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ABSTRACT
The Human antigen R protein (HuR) is an RNA-
binding protein that recognizes U/AU-rich elements
in diverse RNAs through two RNA-recognition mo-
tifs, RRM1 and RRM2, and post-transcriptionally reg-
ulates the fate of target RNAs. The natural prod-
uct dihydrotanshinone-I (DHTS) prevents the asso-
ciation of HuR and target RNAs in vitro and in cul-
tured cells by interfering with the binding of HuR
to RNA. Here, we report the structural determinants
of the interaction between DHTS and HuR and the
impact of DHTS on HuR binding to target mRNAs
transcriptome-wide. NMR titration and Molecular Dy-
namics simulation identified the residues within
RRM1 and RRM2 responsible for the interaction be-
tween DHTS and HuR. RNA Electromobility Shifts
and Alpha Screen Assays showed that DHTS inter-
acts with HuR through the same binding regions as
target RNAs, stabilizing HuR in a locked conforma-
tion that hampers RNA binding competitively. HuR
ribonucleoprotein immunoprecipitation followed by
microarray (RIP-chip) analysis showed that DHTS
treatment of HeLa cells paradoxically enriched HuR
binding to mRNAs with longer 3′UTR and with higher
density of U/AU-rich elements, suggesting that DHTS
inhibits the association of HuR to weaker target mR-
NAs. In vivo, DHTS potently inhibited xenograft tu-
mor growth in a HuR-dependent model without sys-
temic toxicity.
INTRODUCTION
The Human antigen R (ELAVL1, HuR) is an ubiquitously
expressed RNA-binding protein, belonging to the ELAVL
(Embryonic Lethal Abnormal Vision)-like family, that pref-
erentially binds U- andAU-rich elements (AREs) abundant
in the 3′ untranslated regions (3′UTRs) of certain mRNAs.
It is mainly localized within the nucleus (90%), where it
exerts post-transcriptional functions such as splicing (1–4)
and alternative polyadenylation (5–7), and is able to shut-
tle to the cytoplasm, where it mainly regulates the fate of
target RNAs (8). HuR regulates cellular responses to dif-
ferentiation, senescence, inflammatory factors, and immune
stimuli by tightly controlling the post-transcriptional fate of
specific mRNAs (9–12). Notably, HuR binds to and reg-
ulates the half-life of mRNAs and/or the translation of
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mRNAs encoding key inflammatory cytokines and inter-
leukins, such as tumor necrosis factor- (TNF) (13) and
interleukin IL-1, IL-3 (14), IL-6 (15), IL-8, IL-10, IL-4,
CXCL1 (16–18), in turn governing the development and
maturation of B and T lymphocytes (19,20). HuR is highly
expressed in many cancer types, and is believed to promote
tumorigenesis by interacting with mRNAs encoding pro-
teins implicated in cell proliferation and survival, angiogen-
esis, invasion, pharmacoresistance and metastasis (21–27).
The role of HuR in inflammation and cancer has prompted
the search for inhibitors/modulators to interfere with its bi-
ological activity (28–32).
A number of natural and synthetic molecules have been
found to interfere with the formation of HuR/mRNA com-
plexes in vitro (29,32–35). The structural basis of the inter-
action of such molecules with HuR is still poorly character-
ized. HuR contains three highly conserved RNA recogni-
tion motifs (RRMs) among which the first two, RRM1 and
RRM2, bind with high affinity toU/AU-rich RNA (36). By
contrast, the third domain, RRM3, contributes to the inter-
action of HuR with poly(A) tails of target mRNA, and is
believed to be involved in mRNA-induced cooperative as-
sembly of HuR oligomers (37) (Figure 1A). Each RRMdo-
main adopts a 1–1–2–3–2–4 topology with the two
-helices packed in an antiparallel four-stranded -sheet.
Residues at conserved positions located on -strands 1 and
3 are essential for mRNA binding, and are either involved
in stacking interactions with mRNA bases or inserted be-
tween two sugar rings (38). At present, two crystal struc-
tures of the isolated RRM1 domain (PDB codes 3HI9 and
4FXV (39)) and two of the RRM1–RRM2 domains (PDB
codes 4ED5 (40) and 4EGL) are available in the Protein
Data Bank (PDB). Conformational changes occurring on
the tandem RRM1–RRM2 domains are crucial for mRNA
binding (40). As suggested by the crystal structures, the tan-
dem construct adopts an ‘open’ conformation in the free
form and a ‘closed’ conformation when the RRM1 and
RRM2 domains bind mRNA (Figure 1B and C). This hy-
pothesis is supported by SAXS data that show an equilib-
rium among ‘closed’ and ‘open’ conformations for HuR in
solution, in the absence of mRNA. When a target mRNA
sequence is present, the two domains form a stable com-
plex with mRNA and adopt a ‘closed’ globular conforma-
tion around the mRNA strand (41).
Dihydrotanshinone-I (DHTS) is a natural compound
present in Salvia miltiorrhiza that interferes with the forma-
tion of HuR/RNA complexes (31). However, there is cur-
rently no detailed information about the specific interac-
tion of DHTS with HuR or about the perturbations of the
RNA-binding abilities of HuR transcriptome-wide. Here,
we report the analysis of the interaction betweenDHTS and
HuR by NMR, Molecular Dynamics simulation, and mu-
tagenesis experiments. We have characterized the internal
dynamics of the HuR RRM1–RRM2 domains, and have
used this information to analyze the role of the two domains
in ligand binding. In this respect, the identification of the
flexibility of the two domains, RRM1 and RRM2, was par-
ticularly interesting.Moreover, ribonucleoprotein immuno-
precipitation followed by microarray analysis revealed that
DHTS dysregulates HuR by enriching HuR binding to-
wards longer mRNAs highly rich in U/AU-rich 3′UTRs,
including the mRNAs that encode apoptotic and cell-cycle
regulatory proteins in cells, and inhibits cancer cell growth
in vivo.
MATERIALS AND METHODS
Cell lines and reagents
Human cervical adenocarcinoma HeLa cells (ATCC®
CCL2™), colon carcinoma cells HCT116 (ATCC; Man-
assas, VA) were cultured in standard Dulbecco’s Mod-
ified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum (Gibco/Invitrogen), 1% L-glutamine
(Gibco/Invitrogen), 1% penicillin–streptomycin (Invitro-
gen), and growth conditions at 37◦C in 5% humidi-
fied CO2 incubators. Creation and characterization of
CRISPR/Cas9-mediated knockout of the ELAVL1 gene in
HCT116 cells was accomplished as described (42). Dihy-
drotanshinone I (D0947) was purchased from Sigma and
dissolved in ultrapure dimethylsulfoxide (DMSO, Amresco,
N182) to 10 mM final concentration. Antibodies used rec-
ognized HuR (sc-71290; from Santa Cruz Biotechnology),
His tag (anti-6x His (ab1187; from Abcam)) and -actin
(Clone C4; MP Biomedicals).
Cell and tumor growth assays
Transient transfection of cells with a HuR expres-
sion construct (pcDNA3.1/Zeo/HuR-Flag) or empty
vector was accomplished using Lipofectamine Plus
(Gibco/Invitrogen) as described (43) for 48 h, following
addition of 10 M DHTS or vehicle. Cell survival was
assayed using the MTT-based cell growth determination
kit (Sigma-Aldrich) as previously described (30).
Anchorage- and serum-independent growth assays were
accomplished by plating cells (20 cells per well) on 96-well
ultra-low attachment plates (Corning) in in spheroid growth
medium (DMEM supplemented with 10 mM HEPES, N2
supplement (1×; Gibco), B-27 supplement (1×; Gibco), In-
sulin Transferrin Selenium (1×; Gibco), FGF (10 ng/ml;
Gibco) and EGF (20 ng/ml; Gibco)). After 3 days of
growth, spheroids were treated with 10 M DHTS or ve-
hicle for 15 days changing medium every 3 days. Individual
spheroids (n = 5–10/time point) were imaged every 3 days
and area was measured using ImageJ software.
Six week-old athymic nude (Nu/Nu) mice were pur-
chased from Jackson Laboratories and maintained under
sterile conditions in cage micro-isolators according to ap-
proved IACUC guidelines. Parental HCT116 and a repre-
sentative HuR knockout clone (2 × 106 cells) used between
passages 14 and 23 were resuspended in PBS containing
50%Matrigel (Corning) and injected into the dorsal subcu-
taneous tissue (three mice/group with two tumors/mouse).
Mice (three per group) received intraperitoneal (IP) injec-
tions of DHTS (10 mg/kg) dissolved in PBS/5% N-methyl
pyrrolidine (NMP) (Sigma-Aldrich) or vehicle control every
48 h. Tumor volumes and body weight were measured three
times per week using a caliper, and tumor volumes were cal-
culated using the formula: volume = length × width2/2.
Upon termination of the experiment, mice were euthanized
and tumors were harvested.
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Figure 1. Multidomain organization of HuR (A). The RRM1–RRM2 tandem domains (RRM1 aminoacids (aa) Thr20-Pro98 and RRM2 aa Ala106-
Asn186) are separated by a short linker of 7 residues (aa Ser99-Asp105), while RRM3 (aa Trp244-Asn322) is connected to the other two domains by
a long hinge region of about 60 residues (aa Pro187-Gly243), which includes the HuR Nucleocytoplasmic Shuttling (HNS) sequence, responsible for
nuclear/cytoplasmic shuttling of HuR. RRM1 is represented in green, RRM2 in blue and RRM3 in red. The HuRNucleocytoplasmic Shuttling Sequence
(HNS) is indicated in orange. Cartoon representation of the ‘open’ structure of the tandem RRM1–RRM2 domains crystallized in the absence of RNA
(pdb code 4ED5) (B), and of the ‘closed’ structure of the tandem RRM1–RRM2 domains in complex with RNA (pdb code 4EGL) (C). The two domains
and the linker are highlighted with different colors (RRM1 in green, linker in yellow and RRM2 in blue). (D) Comparison of experimental backbone 15NH
R1 values for RRM1–RRM2 (data collected at 298 K, black filled circles) with the calculated values (grey bars) for isolated RRM1 and RRM2 domains
(1), for monomeric RRM1–RRM2 construct (3) and for rigid dimeric adduct (5). Comparison of experimental backbone 15NH R2 values for RRM1–
RRM2 (data collected at 298 K, black filled circles) with the calculated values (grey bars) for isolated RRM1 and RRM2 domains (2), for monomeric
RRM1–RRM2 construct (4) and for rigid dimeric adduct (6). Experimental NOE values for RRM1–RRM2 (data collected at 298 K) (7) and S2 order
parameter calculated with the program TENSOR2 (8).
AlphaScreen and RNA electromobility shift (REMSA) as-
says
Amplified Luminescent Proximity Homogenous Assay (Al-
pha) with a 5′-Biotinylated RNA probe (Bi-TNF, 5′-
AUUAUUUAUUAUUUAUUUAUUAUUUA) was used
with FL-HuR and four studiedmutants. 384-well optiplates
(PerkinElmer; 6007299) were usedwith 20l final volume in
each well. Hooking points of all the respective proteins were
determined. Reagents were used in the nanomolar range us-
ing the AlphaScreen His detection kit (PerkinElmer) in al-
pha buffer (25 mM HEPES pH 7.4, 100 mM NaCl, 0.1%
BSA). Donor and acceptor beads were used at 10 g/ml as
their final concentration, proteins and constructs were ac-
cording to their hooking points and incubated for 1 hour at
room temperature. Plates were read for fluorescence signals
in an Enspire plate reader instrument (PerkinElmer; 2300-
001A), and specific binding was calculated by subtracting
the background, obtained in the absence of the protein.
For REMSA experiments, equimolar concentrations of pu-
rified RRMs and FAM-TNFRNAprobes were used (32) in
REMSA buffer (20 mM HEPES pH 7.5, 50 mM KCl, 0.5
g BSA, 0.25% glycerol) together with reference doses of
DHTS were run on the native Polyacrylamide (6%) gel, in
0.5× TBE buffer at 55 V for 90 min. The gel was analysed
by a Typhoon instrument (GEHealthcare; 00-4277-85 AC).
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R 1, R2 and NOE measurements
The experiments for the determination of 15N longitudi-
nal and transverse relaxation rates and 15N–1H NOE (44)
were recorded at 298 K and 700MHz on 15N-enriched sam-
ples of the RRM1–RRM2 tandem domains of HuR. 15N
Longitudinal relaxation rates (R1) were measured using a
sequence modified to remove cross-correlation effects dur-
ing the relaxation delay (45). Inversion recovery times rang-
ing between 2.0 and 2500 ms, with a recycle delay of 3.5
s, were used for the experiments. 15N transverse relaxation
rates (R2) were measured using a Carr-Purcell-Meiboom-
Gill (CPMG) sequence (45,46), with delays ranging between
8.5 and 237.4 ms and a refocusing delay of 450 s. Longi-
tudinal and transverse relaxation rates were determined by
fitting the cross-peak intensities as a function of the delay to
a single-exponential decay using the Origin software. Het-
eronuclear NOE values were obtained from the ratio of the
peak height for 1H-saturated and unsaturated spectra. The-
oretical predictions of NH R1 and R2 values for RRM1–
RRM2 tandem domains were made using HYDRONMR
(47) and the pdb structure 4ED5 (40), considering (i) the
isolated domains, (ii) the monomeric and (iii) the dimeric
constructs.
Molecular dynamics simulation and analysis
TheHuR-DHTS complex, as issuing from docking calcula-
tions (see SI for details), was submitted to MD simulation
with NAMD (48) using the ff99SBildn Amber force field
parameters (49,50) for proteins and the parameters recently
developed by Allne´r and co-workers for ions (51). Parame-
ters for DHTSwere generated in two steps. Initially, charges
were computed using the restrained electrostatic potential
(RESP) fitting procedure (52). The ESP was first calculated
by means of the Gaussian09 package (53) using a 6–31G*
basis set at Hartree-Fock level of theory, and then the RESP
charges were obtained by a two-stages fitting procedure us-
ing the program RED (54,55). Missing bond, angle, torsion
and improper torsion angle parameters were then generated
using Antechamber (56). The complex was then solvated in
a 15 A˚ layer cubic water box using the TIP3P water model
parameters. Neutrality was ensured by adding five further
Cl− ions. The final system size was∼74 A˚× 93 A˚× 74 A˚ for
a total number of atoms of∼48 000. A 10 A˚ cutoff (switched
at 8.0 A˚) was used for atom pair interactions. The long-
range electrostatic interactions were computed by means of
the particle mesh Ewald (PME) method using a 1.0 A˚ grid
spacing in periodic boundary conditions. The RATTLE al-
gorithm was applied to constrain bonds involving hydrogen
atoms, and thus a 2 fs integration time step could be used.
More details in the Supplementary Methods
RIP-chip protocol
To analyze the influence of DHTS on the interaction of
HuR with endogenous mRNAs, immunoprecipitation (IP)
of endogenous ribonucleoprotein complexes was performed
as described previously (57). Briefly, HeLa cells were lysed
in 20 mM Tris–HCl at pH 7.5, 100 mMKCl, 5 mMMgCl2,
and 0.5%NP-40 for 10 min on ice and centrifuged at 15 000
× g for 10 min at 4◦C. The supernatants were incubated for
2 h at 4◦Cwith protein G Sepharose beads (GEHealthcare)
coated either with anti-HuR or with control IgG antibod-
ies (both from Santa Cruz Biotechnology). The beads were
washed with NT2 buffer (50 mM Tris–HCl [pH 7.5], 150
mMNaCl, 1 mMMgCl2, 0.05% NP-40), followed by incu-
bation with 20 units of RNase-free DNase I for 15 min at
37◦C to remove the DNA. The samples were then incubated
for 15 min at 55◦C with 0.1% SDS–0.5 mg/ml proteinase
K to digest proteins. Microarray analysis was performed in
duplicate (GEO number GSE94360). The RNA from the
IP samples was extracted using phenol–chloroform, precipi-
tated, and used for cDNAmicroarray analysis or RT-qPCR
validation.
Analysis of enriched mRNAs
GC content, length and secondary structure density (com-
puted as the fraction of unpaired nucleotides) for the UTRs
of DEC and INC genes were obtained from the AURA 2
database (58), and plotted with the R software. The enrich-
ment of post-transcriptional regulatory elements was per-
formed with the Regulatory element enrichment feature of
AURA 2. Gene ontology and pathway enrichment analyses
were performed with the Enrichr tool (59) on GO (Biolog-
ical process, Molecular function and Cellular Component)
and pathways (KEGG and Reactome) libraries, using a five
genes overlap and minimum combined score of 2 as signifi-
cance threshold. GO terms were clustered by semantic sim-
ilarity with the GoSemSim R package (60), and the cluster
score computed as the average combined score of compos-
ing terms.
RESULTS
NMR resonance assignment
The 2D 1H–15N HSQC spectrum of tandem RRM1–
RRM2 domains shows well-dispersed signals in agreement
with a uniform and folded protein structure (Supplemen-
tary Figure S1). All the residues (but Pro172), including
those forming the linker region that is crucial for the pro-
tein function, have been assigned (Supplementary Table
S1, BMRB code: 27002). Our assignment of the tandem
RRM1–RRM2 domains was also compared with the ones
reported for the isolated RRM1 domain (61) as in the
RRM1–RRM2 tandem domains (35). The resonances of
residues forming the RRM1 domain are almost the same
in the isolated domain (61), and in the RRM1–RRM2 con-
struct. As reported by Wang and coworkers (35), this ob-
servation suggests that the RRM1 and RRM2 domains do
not interact with each other when they form the tandem
construct. Based on TALOS+ predictions, each domain in
theRRM1–RRM2 construct is constituted by two-helices
and four -strands, in agreement with the previously re-
ported crystal structures of the RRM1 and RRM1–RRM2
domains of HuR (39,40,62) (Supplementary Figure S2).
Internal dynamics of RRM1–RRM2 tandem domains
To characterize protein dynamics, measurements of longi-
tudinal (R1) and transverse (R2) relaxation rates of back-
bone amide nitrogens at 700 MHz, 1H Larmor frequency,
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and 298 K were performed on 15N-enriched samples of the
RRM1–RRM2 construct. Theoretical estimates of R1 and
R2 values were calculated for the following model struc-
tures: (i) the isolated RRM1 (T20-P98) and RRM2 (A106-
N186) domains (Figure 1D, panels 1, 2), (ii) the monomeric
RRM1–RRM2 construct (Figure 1D, panels 3, 4) and, (iii)
the dimeric adduct (Figure 1D, panels 5, 6) (PDB 4ED5).
Figure 1D shows the experimental R1 and R2 values (black
circles) as well as the theoretical ones (grey bars). The com-
parison of experimental R1 and R2 data with theoretical
values calculated for the isolated RRM1 and RRM2 do-
mains shows that experimental R1 values were smaller and
R2 values are larger than their theoretical counterparts (Fig-
ure 1D, panels 1, 2). At the same time, experimental R1 val-
ues were higher than theoretical estimates calculated for the
monomeric construct in solution (Figure 1D, panel 3), in-
dicating that the RRM1–RRM2 construct did not behave
as a rigid body but instead displayed inter-domain flexi-
bility, simulating a protein of lower molecular weight (63–
65). Experimental R2 values were instead slightly higher
than their theoretical counterparts, indicating the occur-
rence of possible aggregation phenomena (Figure 1D, panel
4). On the other hand, experimental R1 values were dra-
matically higher, and R2 dramatically lower than theoret-
ical values calculated for the rigid dimer (Figure 1D, panel
5, 6), suggesting that the RRM1–RRM2 dimer was not
present in solution as a stable complex. Further indication
of the presence of inter-domain flexibility was provided by
the 15N–1HNOE values for the linker residues Ser99 (0.46),
Ser100 (0.34), Glu101 (0.31), Val102 (0.30), Ile103 (0.32)
and Lys104 (0.40) (Figure 1D, panel 7). The small NOE val-
ues of the residues in the linker between the two domains
are evidence of fast motions on ps-ns timescale (faster than
the overall protein-tumbling rate). Very small NOE values
are found also for the N- and C-terminal tails, and for some
residues in the loops of RRM1 (Val56, Ala57, Gly58) and
RRM2 (Gln141, Thr142, Leu145) domains. The order pa-
rameter S2 calculated with the program TENSOR2 (66)
starting from experimental R1, R2 and NOE values is also
reported in Figure 1D, panel 8. The S2 values confirm the
presence of high flexibility between the two domains, and
for some loops within each domain.
DHTS stabilizes HuR in a closed conformation and competes
with mRNA for binding
The interaction of HuR with DHTS was investigated
through solution NMR. The significant precipitation of
the ligand in the solution, occurring at the high concen-
trations required by the NMR analysis, prevented the es-
timation of the affinity constant. Nevertheless, after the ad-
dition of increasing amounts of DHTS to the protein, we
observed a generalized decrease in signal intensity, with
few residues (Thr20, Asn21, Ile52, Ser94, Tyr95, Ala106,
Asn107, Leu108, Ile133, Asn134, Val137, Leu138, Arg147,
Ile152, Phe154, Asp155, Lys182) experiencing a larger ef-
fect. These residues were located in the -platform of both
RRMdomains (Figure 2A andB). The generalized decrease
of signal intensity, and the distribution of affected residues
over the large surfaces of the -platform in each domain
suggested an alteration of the equilibrium among ‘closed’
and ‘open’ conformations upon ligand binding. Specifically,
the decrease of signal intensity was consistent with a mech-
anism where the small molecule stabilizes a ‘closed’ confor-
mation of HuR. After the addition of DHTS to the protein,
only negligible chemical shift changes occur. The residues
experiencing the largest chemical shift perturbations are lo-
cated close to the -platforms (Supplementary Figure S3).
With the dual aim of bringing some insights into
DHTS binding mode and mechanism of action, we car-
ried out a molecular modeling study. We employed a ‘tan-
dem’ approach of docking calculations and molecular dy-
namics (MD) simulations in the attempt to follow the
protein/ligand reciprocal conformational mutations. We
first performed a docking calculation to the whole mRNA
binding surface of HuR by means of AutoDock 4.2, which
converged to a single binding pose. As a result, DHTS was
found at the center of the mRNA binding cleft, which is
shaped by the RRM1 and RRM2 domains (residues 18–95
and 107–185, respectively), and in proximity of the inter-
domain linker. To allow both the ligand and the protein
to fully adapt to each other, we performed an extended
(0.5-s) MD simulation. During the first 100 ns of simu-
lation, DHTS was displaced from its starting position later-
ally along the surface of the RRMdomain -sheets, though
always remaining bound to the HuR surface (Supplemen-
tary Figure S4A and B). This displacement was accompa-
nied by aHuR conformational shift towards a ‘closed’ form
featuring the two RRM domains even closer to each other
(SupplementaryFigure S4C), and establishing further inter-
residues contacts (Supplementary Figure S4D) lacking in
the mRNA-bound conformation, e.g. a salt bridge between
Asp-105 and Arg-153, a backbone hydrogen bond between
Ile-133 and Asn-25 or a hydrophobic contact between Ile-
133 and Ile-23. For the sake of comparison, a further 500
ns MD was performed, starting from the X-ray HuR-RNA
complex. The simulation resulted in an overall greater struc-
tural stability as compared to the HuR–DHTS complex
(Supplementary Figure S5A and B). Furthermore, we ob-
served neither a decrease in the distance between the two
RRM domains nor a significant increase in the number of
inter-domain residue contacts (Supplementary Figure S5C
and D).
In the final HuR–DHTS complex, which remained stable
for the rest of the simulation, DHTS is accommodated in
a narrow, elongated and mostly hydrophobic pocket (Fig-
ure 2C) shaped by residues of the two RRM domain -
sheets (RRM1:Ile-23, Asn-25, Tyr-26, Leu-61, Tyr-63, Phe-
65; RRM2: Asp-105, Ile-133, Asn-134, Arg-153) and of
inter-domain linker (Ile-103 side chain and Lys-104, Arg-97
and Ala-96). The aromatic rings of DHTS establish several
-interactions, among which a cation- interaction with
Arg-153 and a NH– interaction with the Asn-134 side
chain. However, although DHTS is gripped between the
two domains, it does not bind HuR rigidly, but rather gen-
tly sways along the binding surface (Figure 2D). Taken to-
gether, our structural data indicate that DHTS competes
with RNA for the binding to HuR, interacting with the -
platform of both RRM domains in the proximity of the in-
terdomain linker, and thus stabilizing HuR in a closed con-
formation.
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Figure 2. Graphical representation of the intensity changes per residues of RRM1–RRM2 HuR protein (50 M in solution) in the presence of DHTS
(200 M) (A) and surface representation of the closed conformation of HuR (pdb: 4ED5) (B) with the residues exhibiting the highest decreases in signal
intensities highlighted in red. (C) Global view of the HuR (green cartoons)-DHTS (orange spheres) complex. Note how the insertion of DHTS into the
mRNA binding cleft and the further closure of the latter, as compared to the mRNA-bound conformation (yellow), prevents the accommodation of the
mRNA strand (blue ribbons). (D) Theoretical DHTS binding mode, as suggested by our MD simulation. DHTS and HuR residues involved in binding
interactions are displayed as sticks.
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The -platforms of RRM domains are involved in DHTS in-
hibitory activity
To support NMR and molecular modeling that addressed
a specific interacting region on HuR, we produced HuR
protein domains made of the first RRM domain (RRM1),
of the second RRM domain (RRM2), of the RRM1–
RRM2 wild-type RRM domains, and of RRM1 lack-
ing 14 aminoacids at the C-terminus (RRM1, missing
residues from Ser94 to Asn107) and performed in vitro
RNA binding experiments. Some of these residues belong
to the inter-domain linker (Ser99–Asp105) and the others
to the -platform regions of the two domains, where some
aminoacids experienced decreased intensity in the presence
of DHTS (Ser94–Tyr95 in RRM1 and Ala106–Asn107 in
RRM2). HuR domains were produced in Escherichia coli
using the pET42 plasmid (31). We obtained the same purity
for all the protein isoforms (Supplementary Figure S6). As
single domains lose RNA-binding activity very quickly, the
in vitro activity of the single protein domains and of their
combination was evaluated by REMSA, mixing equimo-
lar concentration of each, freshly prepared, with 0.2 M
of the FAM-ARE ssRNA probe (Figure 3A). The RRM1–
RRM2 isoform was used as positive control because it dis-
played a similar Kd (2.62 ± 0.6 nM (31)) to the FL HuR
protein, and because it was used in the NMR experiments
(35). RRM1 retained the capability to recognize mRNA
substrates (40), however with a lower affinity compared to
the RRM1–RRM2 construct, probably indicating a change
in the stoichiometry of cooperative protein binding (Figure
3A, Supplementary Figure S7) (40,62).
Importantly, the RRM1–RNA complex was still sensi-
tive to DHTS. After removing 14 aminoacids, the binding
capacity of RRM1 to RNA was slightly reduced (∼20%)
in comparison with the RRM1 domain (Figure 3A). Con-
versely, RRM1 became resistant to DHTS, suggesting
that this region is important for DHTS inhibitory activ-
ity (Figure 3A). REMSA performed with RRM2 and in
vitro complementation of the two domains (RRM1 + M2
and RRM1 +M2) did not provide information about the
contact region of DHTS (Supplementary Figure S7B–D).
By using fluorescence polarization, we analyzed the bind-
ing kinetics of proteins (200 nM) toward the FAM–ARE
RNA probe (100 nM). We confirmed that full-length HuR
and RRM1–RRM2 tandem domains behave almost simi-
larly (average Kobs ∼4 min), reaching equilibrium after 10
min. On the other hand, the RRM1 domain rapidly rec-
ognized the substrate (Kobs ∼1 min), but this affinity was
significantly impaired in the RRM1 construct (Kobs of
∼8 min) (Figure 3B). Circular dichroism (CD) experiments
performed at 10 M concentration of both reagents, and
NMR measurements ruled out a putative interaction be-
tween DHTS and RNA (Supplementary Figure S8A and
B). Collectively, these findings show that the residues form-
ing the -platform and placed at the C-terminal in RRM1
domain are critical for RNA binding and the inhibitory ac-
tivity of DHTS.
Single point mutations in the HuR–DHTS interacting region
abolishes DHTS efficacy
Based on NMR data and an initial raw model of DHTS
binding as derived by docking calculations, residues Ser94,
Asn107, Ile133 and Asn134 of the RRM1–RRM2 inter-
domain region were mutated to probe their relevance for
DHTS binding.We produced residue-to-Alaninemutations
in the full-length HuR sequence by site-directed mutagen-
esis (67) (Supplementary Figure S9). The preservation of
the folding of the mutants was assessed by 1H 1D NMR
spectra (Supplementary Figure S10). By reacting equimolar
amount of wild-type HuR or muteins with 0.2 M FAM–
ssRNA, we observed an inhibitory effect of DHTS only
with wild-type HuR, while any functional single point mu-
tation led to resistance to DHTS (Figure 3C). Interestingly,
we observed a qualitatively distinct binding profile among
muteins: at least three discrete supershifts, numbered ac-
cording to the molecular weight (1 being the lightest, 2,
and 3), were detectable for wild-type HuR. Supershift 3 was
markedly enriched in N134A and N107A, and to a lesser
extent in I133A muteins (Figure 3C). This behavior could
result from a higher efficiency in recognition and dimeriza-
tion along the mRNA substrate, or alternatively from an
aggregation-prone tendency of muteins that therefore ag-
gregate on the same molecule of RNA probe. Indeed, mu-
tants showed significantly lower Kd values, i.e. an increased
affinity in saturation binding experiments with respect to
wild-typeHuR (Figure 3D, Supplementary Figures S11 and
S12). Additionally, the raw signals at the hook point val-
ues for protein and RNA probes were significantly reduced
in intensity compared to wild-type HuR, indicating a sub-
optimal assay environment, compatible with ligand self-
aggregation (68).
According to these data, when Ser94, Asn107, Ile133 and
Asn134 are mutated into Alanine, DHTS does not bind to
any mutein. The four residues are thus crucial in providing
the required flexibility to HuR for its mRNA binding func-
tion.
DHTS prevents HuR binding to low AU-rich density mRNA,
but enriches it to high AU-rich density species
We evaluated the ability of DHTS to disrupt the inter-
action of HuR with its target mRNAs by employing a
transcriptome-wide approach. We performed a RIP-chip
(ribonucleoprotein immunoprecipitation followed by mi-
croarray) experiment in HeLa cells, and observed that, out
of the 2306 mRNAs bound to HuR, DHTS only reduced
binding of 79 transcripts. Conversely, 558 mRNAs were en-
riched after treatment with DHTS. Therefore, contrary to
our expectations, we observed an overall enrichment ofmR-
NAs bound to HuR after treatment with DHTS. We rea-
soned that DHTS could displace mRNAs that had lower
affinity to HuR than DHTS itself had, and, paradoxically,
provide the opportunity for mRNAs with higher affinity
for HuR than DHTS to bind in higher copy numbers to
HuR.We observed that HuR-boundmRNAs had relatively
higher frequency of U/AU-rich segments compared to the
frequency transcriptome-wide, as expected (69). However,
the U/AU density in UTRs in enriched mRNAs was sig-
nificantly higher than that in downregulated mRNAs (Sup-
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Figure 3. The inter-domain region between RRM1 and RRM2 is crucial for RNA and DHTS binding. (A) On left, representative REMSAs of at least
three independent protein preparations of recombinant RRM1 + RRM2 (M1 +M2) domains, RRM1 (M1), RRM2 (M2), RRM1–RRM2 (M1M2) HuR
proteins. REMSAs were performed with 0.2 Mof protein, 0.2 Mof Cy-3 RNA probe and DMSO or DHTS at indicated doses. On right, representative
REMSA performed with 2.5 M of RRM1 and 75 fM of probe RNA titrated with DHTS (concentration as shown in the legend). Densitometric
quantification plotted below represents specific HuR–RNA binding challenged by DHTS. Mean ± SD refers to three independent experiments (n = 3,
* indicates t-test P-value < 0.05). (B) Kinetic saturation binding experiment by fluorescence polarization. 200 nM wild-type protein or mutants were
incubated with FAM-ARE RNA probe (100 nM). Full-length HuR and RRM1–RRM2 tandem domains (M1M2) have similar Kobs. RRM1 (M1) is
binding faster (Kobs of ∼1 min), ) but deletion of the inter-domain region abolishes the binding properties of RRM1 (M1) (Kobs of ∼8 min). (C) RNA-
and DHTS-interacting amino acids are crucial for DHTS and RNA binding, and for protein dimerization. Representative REMSAs of at least three
independent protein preparations of recombinant full-length HuR and indicated muteins. REMSAs were performed with 0.2 M of protein, 0.2 M of
Cy-3 RNA probe, and DMSO or 5 MDHTS.Muteins are insentive to DHTS and show different binding patterns to the RNA probe. (D) Representative
REMSAs of at least three independent protein purification performed with increasing concentration of WT and HuR single point mutant N134A with 75
fM of probe RNA.
plementary Table S2, median of 1.37 ARE nts/100 nts for
enriched genes, 0.97 for depleted genes; mean of 2.24 ARE
nts/100 nts for enriched genes, 1.49 for depleted genes; max-
imum of 81.97 ARE nts/100 nts for enriched genes, 7.92 for
depleted ones). Moreover, the highest differences were ob-
served in the 3′UTR (Figure 4A), where the percentage of
AU bases increased from 58% (depleted) to 65% (enriched).
Additionally, 3′UTRs, but not 5′UTRs, were significantly
longer for the enriched mRNAs (Figure 4B), while no dif-
ferences in the density of secondary structure elements were
observed (Figure 4C).
Functional analyses of depleted genes provided no con-
siderable enrichment, due to the small size of the set and
because it was partially composed of unannotated mRNAs.
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Figure 4. Enriched and depleted mRNAs and their UTRs have distinct properties. (A) Distribution of GC content for depleted (dec) and enriched (inc)
UTRs, with Wilcoxon test-P-values of the differences. (B) Length distribution for depleted (dec) and enriched (inc) UTRs, with Wilcoxon test-P-values
of the differences. (C) Secondary structure density (computed as the fraction of unpaired nucleotides) of depleted (dec) and enriched (inc) UTRs, with
Wilcoxon test-P-values of the differences. (D) Gene Ontology enrichment analysis for the enriched gene set. Number of genes belonging to each terms
cluster is shown at the end of the corresponding bar. Mean score represents the mean of the Enrichr combined score for all belonging terms. GO classes
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Enriched mRNAs (Figure 4D and E, Supplementary Ta-
ble S3) showed that, during DHTS treatment, HuR bound
preferentially to mRNAs encoding proteins with functions
in the regulation of gene expression, cell cycle progres-
sion, and apoptosis. Data validation also suggested that
the changes in HuR binding were independent of changes
in total mRNA levels, as mRNA abundance was generally
unchanged (Figure 4F and G). In summary, the ability of
DHTS to displace HuR-bound RNAs was specifically lim-
ited tomRNAswith a low affinity for HuR, which generally
displayed lower AU content in their 3′UTRs.
DHTS is effective on HuR-positive models in vitro and in vivo
To evaluate this mechanism of action, in which a lim-
ited displacement of RNAs from HuR may be effec-
tive in HuR-dependent tumor growth, we studied tumor
growth in vitro and in vivo. HCT116 colon cancer cells
were used as a model, based on high endogenous lev-
els of HuR and their sensitivity to HuR inhibition (30).
Creation and characterization of CRISPR/Cas9-mediated
knockout of the ELAVL1 gene in HCT116 cells was ac-
complished as described (42). HCT116 and HuR-knockout
cells (HCT116HuR) were grown under anchorage- and
serum-independent conditions to facilitate tumorspheroid
growth, and HuR was observed to be needed for tumor-
sphere growth (Figure 5A and B). In the presence of
DHTS, growth of HCT116 spheroids was attenuated 2-
fold, whereas DHTS did not impact HCT116HuR sphere
growth (Figure 5A and B). To test the effects of DHTS on
tumor growth in vivo, mice bearing HCT116 cell xenografts
received IP injections of DHTS (10 mg/kg body weight)
or vehicle every 48 h. Over the course of the experiment,
DHTSwas well tolerated andmice did not display any signs
of acute toxicity and maintained similar weights. Signifi-
cant anti-tumor effects of DHTS were observed, with ap-
proximately a 4-fold reduction in tumor size (Figure 5C
and D). Additionally, the efficacy of DHTS was strictly
dependent on the presence of HuR. HCT116HuR cells
grew significantly more slowly and formed smaller tu-
mors, but were completely insensitive to DHTS. Further-
more, this decreased growth sensitivity of DHTS in HuR-
deficient cells could be restored with expression of HuR
in HCT116HuR cells (Figure 5E and F). These results
indicate that DHTS has significant antitumor activity in
vitro and in vivowithout major systemic toxicity, along with
demonstrating specificity of HuR inhibition.
DISCUSSION
Previous efforts targeted towards HuR disruptors (28–
30,32,70) identified small molecules that can inhibit the
HuR–RNA interaction in the nanomolar range. Here, we
have characterized from a structural and functional per-
spective the mechanism of action of DHTS, a disruptor of
the HuR–RNA interaction, identifying the protein regions
that promote the interaction, and providing hints for the
rational design of more potent HuR inhibitors. Addition-
ally, we showed the cellular effects of DHTS treatment on
HuR ability to bind mRNAs, and we described a paradox-
ical enrichment of mRNAs containing longer 3′UTRs with
increased AU content. Such effects result in dysregulation
of HuR function, specific to cells that are strictly depen-
dent on HuR function. Starting from the relaxation mea-
surements of RNA-free protein in solution, we described
the events preceding RNA binding. The analysis of NMR
relaxation data indicates that the free RRM1–RRM2 con-
struct is largely monomeric in solution. However, the ob-
served R2 values are slightly higher than those expected for
a monomeric protein, suggesting the presence of an equi-
librium with a fraction of protein experiencing a larger ro-
tational correlation time. On the other hand, the discrep-
ancy of observedR1 data with respect to the theoretical val-
ues calculated for a rigid RRM1–RRM2 monomer are ex-
plained by the presence of inter-domain flexibility. The low
NOE values suggest a significant conformational plasticity
of the protein that is needed for mRNA binding. Therefore,
even if it is reported that the RRM1–RRM2 tandem con-
struct forms a separated functional unit from the RRM3
domain (71), RRM1 and RRM2 domains are not rigidly
held together but undergo independent motions that can fa-
cilitate the recognition of the RNA partner. This confirms
observations from the crystal structure of non-complexed
HuR, where no contacts between the two domains were de-
tected (40,62) and supports earlier results that phosphory-
lation at the linker (e.g. Ser100) had a profound impact on
HuR binding to target mRNAs (72). Moreover, the large
R1 values and small NOE values seen for the linker indicate
that this region highly influences the conformational change
of the protein from an open/flexible free conformation to-
wards a closed one bound to mRNA.
As previously reported (40), binding of mRNA to HuR
can occur starting from the open/flexible state of the pro-
tein, whereHuRfirst binds themRNA strand via its RRM1
domain. As a result of the subsequent conformational
change, the linker and the RRM2 domain bind the mRNA
filament to form a stable complex (40). Therefore, the linker
takes part in the binding allowing the reciprocal reorienta-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
found in each cluster are represented by the bars color. (E) KEGG and REACTOME pathway enrichment analysis for the enriched gene set. Number of
genes belonging to each pathway is shown at the end of the corresponding bar. The score is the Enrichr combined score for the pathway. Pathway database
of each entry is represented by the bars color. RIP of HuR in DHTS-treated HeLa cells. (F) Microarray data for selected targets. Fold enrichment of each
mRNA during DHTS treatment is reported, black bars represent microarray values obtained. (G) Validation of microarray data by RT-qPCR. Gray bars
represent fold enrichment of each mRNA during DHTS treatment compared with the control condition (DMSO). Comparison between microarray (F)
and RT-qPCR data (G) shows similar results for enriched transcripts (PABPC1, YTHDF1 and UPF2 mRNAs), unchanged transcripts (CASC3 mRNA)
and depleted transcripts (BRIP1 and TBCCD1mRNAs). In RT-qPCR validation experiments,RPLP0mRNAwas used as an endogenous control mRNA
that did not bind to HuR. Error bars represent SD. P-value is *<0.05. **<0.001. Mirocrarray experiments were done in duplicate (n = 2), qRT-PCR in
triplicate (n= 3). (H) RT-qPCR analysis of mRNAs bound to of HuR showing no changes in total expression levels after DHTS treatment.RPLP0mRNA
was used as an endogenous control. Error bars represent SD. Experiments were done in triplicate (n = 3).
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Figure 5. DHTS efficacy relies on HuR presence in vivo. (A) Spheroid growth of parental HCT116 (HCT116) and HuR-knockout cells (HCT116HuR)
treated with DHTS (10 M) or vehicle. DHTS was added after 3 days of culture in spheroid growth medium on ultra-low adherence substrate and spheroid
growth was tracked by imaging for 15 days. P-value is **<0.01, ***<0.001, n.s. = not significant. (B) Representative tumorsphere images from day 0 and
day 15 of DHTS treatment. Scale bar = 100 m. (C) Tumor growth of parental HCT116 and HuR-knockout cells (HCT116HuR) xenografts in nude
mice treated with 10 mg/kg DHTS or vehicle control every 48 h. P-value is ***<0.001, n.s. = not significant. (D) Representative tumors excised at day 31
are shown. (E) HuR-knockout cells (HCT116HuR) were transfected a HuR-expression construct (+HuR), along with empty vector transfected parental
HCT116 and HCT116HuR cells. Cells were treated with DHTS (10 M) or vehicle, and cell growth was assessed 6 days after the treatment using MTT
assay. Cell survival was normalized to the respective control and are the average of three experiments. P-value is **<0.01, ***<0.001. (F) Western blot
showing HuR complementation in HCT116HuR+HuR cells and absence of HuR in HCT116HuR cells. Actin was used as a loading control.
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tion of the two domains and establishing interactions with
the RNA strand. Addition of DHTS to unbound HuR re-
sults in a generalized decrease of the signal intensity of the
NMR resonances, with some residues experiencing larger
effects. It is likely that this behavior is due, at least in part,
to a change in the conformational dynamics of the protein.
Accordingly, upon complex formation with DHTS, in our
MD simulation we observed a rather limited inter-domain
flexibility, as a result of the shift in the conformational equi-
librium between HuR forms in favor of a closed conforma-
tion. This result was not anticipated since, at least in princi-
ple, a change in the conformational dynamics of HuR could
also have been achieved by stabilizing an open formofHuR.
Indeed, residues located on the -platforms of RRM1 and
RRM2domains, in the same regions involved in the binding
with the mRNA strand, experience a deep quenching.
In our MD simulation, we observed a further closure
of the RNA-binding groove, as compared to the RNA-
bound conformation of HuR, and an ensuing increase in
the number of inter-domain contacts, which could explain
why the largest decreases in signal intensity were observed
in residues belonging to these -platforms. Deletion of the
C-terminus region of RRM1 reduces the binding affinity
of RRM1 to the mRNA probe but, importantly, abolishes
the interaction between RRM1 and DHTS. This experi-
mental validation of the NMR data and molecular mod-
eling points to the residues next to the linker as being key
structural elements responsible of the interaction between
DHTS and HuR. Single aminoacid mutagenesis of Ser94,
Asn107, Ile133, and Asn134 into alanine highlighted the
importance of these residues in maintaining the equilib-
rium between the free protein in the monomer/dimer form
and the closed-bound-to-RNA protein dimer, avoiding its
aggregation on the RNA target. Interestingly, muteins are
fully resistant to DHTS, further supporting that this small
molecule competes for the same protein regions interact-
ing with the target RNA. Collectively, these results suggest
that DHTS stabilizes an unproductive ‘closed’ conforma-
tion of HuR and prevents the physiological re-orientation
of the two domains needed to bind the target mRNA. Sta-
bilization of such ‘closed’ conformation alters the protein
dynamics, producing the observed generalized decrease of
signal intensity of the resonances observed upon the addi-
tion of DHTS to the RRM1–RRM2 tandem domains. Un-
fortunately, the non-optimal solubility of DHTS hampered
the quantitative assessment of its Kd.
In other experiments, we characterized the ability of
DHTS to inhibit HuR activity in vitro, to modulate its
post-transcriptional function in cell models, and its speci-
ficity towards other RNA-binding proteins. Additionally,
we observed that DHTS inhibits the association step of
HuR to its target RNAs, and that its cytotoxicity against
cancer cells was HuR-dependent (31). The stable ‘closed’
form of the protein blocks the access to HuR for low affin-
ity target RNAs. Indeed, paradoxically, the mRNAs with
longer 3′UTR and higher U/AU content were more abun-
dantly loaded onHuR after DHTS treatment, as they likely
bind more avidly to HuR than DHTS itself. The levels of
HuR-target RNAs were not changed during DHTS treat-
ment, so a ‘post-binding’ mechanism of regulation can
be inferred. Nevertheless, DHTS-dependent HuR dysreg-
ulation has a strong anti-cancer activity in vivo, as ob-
served using a xenograft model of colon cancer (HCT116
cells). These findings are consistent with other results us-
ing colon, leukemia, cervical, and breast cancer cells, and
indicate that DHTS can penetrate tumors effectively (73–
76). The absence of systemic toxicity in treated animals
supports the idea that general inhibition of HuR by small
molecules can be a therapeutic avenue for future efforts, al-
though the effects on the immune system should be eval-
uated in a non-immuno-compromised mouse model. No-
tably, HCT116HuR knockout cells in vivo showed a lim-
ited ability to develop tumors, but the extent of DHTS
growth inhibition on these tumors did not match the effects
on WT tumors. While we cannot discount that loss of HuR
may impact cancer cell drug uptake, these results indicate in
vivo specificity of DHTS and support the view that DHTS
requires HuR for its antitumor influence. Finally, experi-
mental and theoretical studies here reported suggest that the
mechanism of action of DHTS is that of a competitive in-
hibitor of mRNA binding to HuR. These observations will
be the ground for a rational design and synthesis of more
potent small-molecule HuR disruptors.
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